HYOF) said on Thursday that it expects full-year revenues to come in ahead of expectations, marking a return to growth as the neuroscience imaging group builds momentum across its commercial strategy. The company, which provides artificial intelligence-driven analytics to support drug development in neurological disorders, said revenues for the year ending 30 September are set to be at least £6.3 million. 